ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 14 to Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 10,056,844 shares of CRISPR Therapeutics AG common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: ARK Investment Management LLC and Catherine D. Wood each report beneficial ownership of 10,056,844 shares of CRISPR Therapeutics AG common stock.
  • Percent of class: The reported holdings represent 10.40% of the class of securities, according to the filing.
  • ARK sole voting power: ARK Investment Management LLC holds sole voting power over 9,466,222 shares and shared voting power over 143,106 shares.
  • ARK sole dispositive power: ARK Investment Management LLC holds sole dispositive power over all 10,056,844 shares, with no shared dispositive power reported.
  • Catherine D. Wood's power: Wood reports zero sole voting or dispositive power, with shared voting power of 9,609,328 shares and shared dispositive power of 10,056,844 shares.
  • Notable client interest: The filing states that "no client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Innovation ETF, a series of a Delaware statutory trust."
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.

ARK Investment Management and Wood Disclose CRISPR Therapeutics Position in Amendment No. 14

ARK Investment Management LLC, a Delaware-organized investment adviser, and Catherine D. Wood, identified as Chief Executive Officer and Chief Investment Officer, filed Amendment No. 14 to Schedule 13G on November 13, 2026, covering common stock of CRISPR Therapeutics AG (CUSIP H17182108). The filing was triggered by an event dated September 30, 2026, and reports combined beneficial ownership of 10,056,844 shares, representing 10.40% of the class, according to the disclosure.

The filing distinguishes the voting and dispositive powers held by each reporting person. ARK Investment Management LLC reports sole voting power over 9,466,222 shares, shared voting power over 143,106 shares, and sole dispositive power over the full 10,056,844 shares. Catherine D. Wood, filing as a holding company and individual (types HC and IN), reports no sole voting or dispositive power, but shared voting power of 9,609,328 shares and shared dispositive power of 10,056,844 shares. Both reporting persons are based at 200 Central Avenue, St. Petersburg, FL 33701, per the filing.

Regarding the purpose of holding, the filing certifies that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." On client interest, the filing identifies ARK Innovation ETF, a series of a Delaware statutory trust, as the only ARK client with an interest in the reported securities exceeding 5 percent of the class. The filing was signed by Kathleen Fontano, Chief Compliance Officer of ARK, and by Catherine D. Wood, on November 13, 2026.

What Was Disclosed

ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 14 to Schedule 13G disclosing beneficial ownership of 10,056,844 shares, or 10.40%, of CRISPR Therapeutics AG common stock, with the event date of September 30, 2026, and ARK Innovation ETF identified as the sole client with a greater-than-5% interest.